Literature DB >> 8047849

The importance of G1m and 2 allotypes for the IgG2 antibody levels and avidity against pneumococcal polysaccharide type 1 within mono- and dizygotic twin-pairs.

H B Konradsen1, V A Oxelius, M Hahn-Zoric, L A Hanson.   

Abstract

Eighty-two mono- or dizygotic Caucasian twins vaccinated with a 23-valent pneumococcal vaccine, who had previously had their IgG2 antibody levels to pneumococcus type 1 determined before and after vaccination, were included in this study. Their IgG2 antibody levels were related to their G1m and G2m allotypes/phenotypes and their Gm amounts. Eight different Gm phenotypes were found and characteristically IgG2 antibody levels were related to them. G2m (n) homozygotic twins had significantly higher IgG2 levels than heterozygotic twins who had significantly higher levels than G2m (-n) homozygotic twins (P < 0.05). The G1m allotype, on the other hand was without influence on the IgG2 levels and so were the Gm amounts among G2m (n) heterozygotic twins. The IgG2 antibody avidities were not related to Gm allotypes but significantly correlated to IgG2 levels (P = 0.05). Finally, a highly significant intra-pair correlation was found for avidity in the monozygotic twins supporting a genetic regulation of avidity (P < 0.002). These results may explain our earlier findings that IgG2 antibody levels after pneumococcal vaccination are significantly more closely correlated within mono- compared to dizygotic twins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047849     DOI: 10.1111/j.1365-3083.1994.tb03458.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Differential idiotype utilization for the in vivo type 14 capsular polysaccharide-specific Ig responses to intact Streptococcus pneumoniae versus a pneumococcal conjugate vaccine.

Authors:  Jesus Colino; Leah Duke; Swadhinya Arjunaraja; Quanyi Chen; Leyu Liu; Alexander H Lucas; Clifford M Snapper
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

Review 2.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  Antibody response to the Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in healthy and infection-prone individuals with IgG3 subclass deficiency.

Authors:  M Hahn-Zoric; M Ulanova; V Friman; J Björkander; V A Oxelius; A Lucas; L A Hanson
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

Review 5.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

Review 6.  The genetic regulation of infant immune responses to vaccination.

Authors:  Melanie J Newport
Journal:  Front Immunol       Date:  2015-02-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.